Legend Biotech Corp (9LBy)

Currency in EUR
33.60
-0.40(-1.18%)
Closed·
9LBy is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
33.2033.60
52 wk Range
24.6052.50
Key Statistics
Bid/Ask
33.40 / 33.80
Prev. Close
34.4
Open
33.4
Day's Range
33.2-33.6
52 wk Range
24.6-52.5
Volume
312
Average Volume (3m)
519
1-Year Change
-31.71%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9LBy Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Legend Biotech Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Legend Biotech Corp Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Compare 9LBy to Peers and Sector

Metrics to compare
9LBy
Peers
Sector
Relationship
P/E Ratio
0.0x−3.4x−0.5x
PEG Ratio
0.00−0.190.00
Price/Book
0.0x2.5x2.6x
Price / LTM Sales
0.0x12.7x3.3x
Upside (Analyst Target)
0.0%161.4%45.4%
Fair Value Upside
Unlock20.7%7.7%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

9LBy Income Statement

People Also Watch

44.430
SMR
-11.51%
25.91
CNC
-0.61%
168.10
CRCL
-8.40%
52.460
ASTS
-1.34%
71.49
OKLO
-6.66%

FAQ

What Stock Exchange Does Legend Biotech Corp Trade On?

Legend Biotech Corp is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Legend Biotech Corp?

The stock symbol for Legend Biotech Corp is "9LBy."

What Is the Legend Biotech Corp Market Cap?

As of today, Legend Biotech Corp market cap is 6.17B.

What Is Legend Biotech Corp's Earnings Per Share (TTM)?

The Legend Biotech Corp EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 9LBy a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Legend Biotech Corp Stock Split?

Legend Biotech Corp has split 0 times.

What is the current trading status of Legend Biotech Corp (9LBy)?

As of 03 Aug 2025, Legend Biotech Corp (9LBy) is trading at a price of 33.60, with a previous close of 34.40. The stock has fluctuated within a day range of 33.20 to 33.60, while its 52-week range spans from 24.60 to 52.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.